Hydrocortisone

• A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Ended
  2022-500721-32-01 Phase II 2 countries Gcp-Service International West GmbH
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ… Ended
  2022-500027-76-00 Phase II 1 country Akershus University Hospital
• The RESCUE study Ended
  2024-518272-30-00 Phase IV 1 country Rigshospitalet
• Hydrocorticose and vasopressin in post-resuscitation syndrome Ended
  2024-516373-77-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended
  2022-502937-24-00 Phase III 18 countries Abbvie Deutschland GmbH & Co. KG
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended
  2023-507889-89-00 Phase III 13 countries Universitair Medisch Centrum Utrecht
• VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial. VAST-A Halted
  2025-521283-35-00 Phase III 1 country Tiohundra AB
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 Phase III 1 country Celltrion Inc.
• Understanding the Neurobiology of Pharmacologically-induced Acute Stress on Ethical Decisions Ended
  2023-508731-31-01 Phase IV 1 country Universitair Medisch Centrum Utrecht
• Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended
  2023-503522-40-01 Phase II 2 countries Anaptysbio Inc.
• An open-label, cross-over, multi-site, prospective, phase IIb study of effects on circadian rhythms and quality of life of modifieddual-rele… Ended
  2023-503584-42-00 Phase II 1 country Royal College Of Surgeons In Ireland
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 Phase III 8 countries InflaRx GmbH
• Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to… Ended
  2022-503066-74-00 Phase I (FiH) 5 countries Bioinvent International AB
• Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants with Congenital Adrenal Hyperplasia Ended
  2023-503488-40-00 Phase II 2 countries Crinetics Pharmaceuticals Inc.
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended
  2023-503830-27-00 Phase II 3 countries Allogene Therapeutics Inc.
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 Phase II 2 countries Allogene Therapeutics Inc.
• Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder Ended
  2024-515475-35-00 Phase II 1 country Universitaetsmedizin Goettingen
• REPLACE - A multi-centre, randomised, double-blinded, placebo controlled 16-weeks study to compare the effect of hydrocortisone and placebo … Ended
  2024-513822-53-00 Phase IV 1 country Odense University Hospital
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use… Ended
  2023-503771-13-00 Phase II 12 countries Spruce Biosciences Inc.
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of… Ended
  2023-503770-21-00 Phase II 12 countries Spruce Biosciences Inc.
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS) Ended
  2023-503898-38-00 Phase III 7 countries Eli Lilly & Co.
• VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial. VAST-A Expired
  2022-500137-89-00 Phase III 1 country Tiohundra AB

Showing 25–46 of 46 trials